Beta-blockers are questioned by emerging evidence as a preferred rate-control therapy in patients with atrial fibrillation.
Emerging evidence challenges the current strong recommendation for beta-blockers as the preferred rate-control therapy in patients with atrial fibrillation.
Tasa de eventos absoluta: 0% vs 0%
Atrial fibrillation is closely associated with heart failure and adversely affects outcomes. Beta-blockers are strongly recommended to avoid rapid ventricular conduction and tachycardia-induced cardiomyopathy. In this Viewpoint article, we discuss an emerging body of evidence that questions beta-blockers as a preferred rate-control therapy in patients with atrial fibrillation.
Meyer et al. (Wed,) reported a other. Beta-blockers are questioned by emerging evidence as a preferred rate-control therapy in patients with atrial fibrillation.